Loblaw Companies Ltd (LBLCF) Given Consensus Rating of “Buy” by Analysts

Share on StockTwits

Loblaw Companies Ltd (OTCMKTS:LBLCF) has been given an average recommendation of “Buy” by the six analysts that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company.

LBLCF has been the subject of several recent research reports. Raymond James restated a “buy” rating on shares of Loblaw Companies in a report on Friday, February 22nd. Desjardins upgraded Loblaw Companies from a “hold” rating to a “buy” rating in a report on Thursday, May 2nd.

LBLCF stock opened at $52.35 on Wednesday. Loblaw Companies has a 1-year low of $38.65 and a 1-year high of $52.35.

About Loblaw Companies

Loblaw Companies Limited, a food and pharmacy company, engages in the grocery, pharmacy, health and beauty, apparel, general merchandise, financial services, and wireless mobile products and services businesses in Canada. It operates in two segments, Retail and Financial Services. The Retail segment operates corporate and franchise-owned retail food, and associate-owned drug stores comprising in-store pharmacies, other health and beauty product stores, apparel stores, and other general merchandise stores, as well as supports the PC Optimum reward program.

Read More: Marijuana Stocks

Analyst Recommendations for Loblaw Companies (OTCMKTS:LBLCF)

Receive News & Ratings for Loblaw Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loblaw Companies and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Soliton Inc’s  Lock-Up Period To Expire Tomorrow
Soliton Inc’s Lock-Up Period To Expire Tomorrow
Nicholas Devlin Sells 6,004 Shares of Majestic Wine PLC  Stock
Nicholas Devlin Sells 6,004 Shares of Majestic Wine PLC Stock
Short Interest in Xeris Pharmaceuticals Inc  Decreases By 5.1%
Short Interest in Xeris Pharmaceuticals Inc Decreases By 5.1%
Zacks Investment Research Downgrades Genmab A/S  to Hold
Zacks Investment Research Downgrades Genmab A/S to Hold
Kala Pharmaceuticals  Lowered to “Hold” at Zacks Investment Research
Kala Pharmaceuticals Lowered to “Hold” at Zacks Investment Research
Hanger  Stock Rating Upgraded by Zacks Investment Research
Hanger Stock Rating Upgraded by Zacks Investment Research


 
© 2006-2019 Zolmax.